Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Alnylam Initiates Phase IIb Clinical Trial Of ALN-RSV01 In Adult Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Infection
Entering text into the input field will update the search result below Entering text into the input field will update the search result below About Premium Create free account Log in Ooops... Something went wrong while loading this page.Reload Seeking Alpha - Power to Inve...
Tekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results At American Society Of Clinical Oncology (ASCO) Annual Meeting